# US 10,870,690 B2 · Protein therapeutant and method for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,870,690 B2
- Document ID: US10870690B2
- Status: Granted
- Kind: B2
- Application number: 15/609,370
- Filed: 2017-05-31
- Published: 2017-09-21
- Granted: 2020-12-22
- Earliest claimed: 2013-04-02
- Applicants: Yihong Zhou
- Inventors: Yihong Zhou
- Web page: https://patentgrep.com/patent/US10870690B2

## CPC

- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to compositions for treating cancer by having one or more activities of inhibiting cancer growth, inhibiting cancer cell invasion, and inhibiting cancer recurrence.

## Claims

### Claim 1

A method for treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising an isolated polypeptide comprising an amino acid sequence selected from the group consisting of: a) SEQ ID NO:14; b) SEQ ID NO: 1; and c) SEQ ID NO: 2, wherein the cancer is a glioma.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method results in at least one activity selected from the group consisting of inhibition of cancer cell invasion, inhibition of cancer cell growth and inhibiting cancer cell recurrence.

### Claim 3 (depends on 1)

The method of claim 1, wherein the tumor of the subject is characterized as-having activation of epidermal growth factor receptor (EGFR).

### Claim 4 (depends on 1)

The method of claim 1, wherein the cancer is selected from the group consisting of a low grade glioma, a medium grade glioma, a high grade glioma, and human glioblastoma multiforme.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer is a glioblastoma multiforme.

### Claim 6 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the composition is administered to a subject by intra-tumoral injection.

### Claim 7 (depends on 1)

The method of claim 1, wherein the tumor of the subject is characterized as having activation of NOTCH.

### Claim 8 (depends on 1)

The method of claim 1, wherein the tumor of the subject is characterized as having activation of AKT.

### Claim 9 (depends on 1)

The method of claim 1, wherein the tumor of the subject is characterized as having activation of an extracellular matrix metallopeptidase.